Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
SymbioCellTech, LLC maintains 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a lack of overlap in the current prosecution pipeline. PURDY, KYLE A is the busiest examiner for the portfolio, currently managing 1 pending office action.
The distribution of 2 pending office actions across 2 distinct art units suggests that the company's intellectual property interests are spread across different specialized niches within the broader Biotechnology & Pharmaceuticals field. Since the busiest examiner pending count is 1, the workload is distributed between the 2 distinct examiners. This requires the company to adapt its prosecution tactics to the specific requirements of 2 different examiners simultaneously. The 2 distinct examiners provide a variety of perspectives on the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PURDY, KYLE A | 1 | 41.0% | +35.9% |
| BEHARRY, ZANNA MARIA | 1 | 24.7% | +56.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263934 | Cell Clusters Comprising Stem and Islet Cells, Methods of Making, and Treatment of Diabetes Mellitus Therewith | BEHARRY, ZANNA MARIA | 36d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263934 | Cell Clusters Comprising Stem and Islet Cells, Methods of Making, and Treatment of Diabetes Mellitus Therewith | BEHARRY, ZANNA MARIA | 36d |
| 18997284 | Species-Specific Tissue Culture Medium for the Propagation of Cells | PURDY, KYLE A | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18997284 | Species-Specific Tissue Culture Medium for the Propagation of Cells | PURDY, KYLE A | 1611 | §103 | Non-Final OA | — | Pending | Jan 21, 2025 |
| 18263934 | Cell Clusters Comprising Stem and Islet Cells, Methods of Making, and Treatment of Diabetes Mellitus Therewith | BEHARRY, ZANNA MARIA | 1632 | §102§112 | Non-Final OA | 36d | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial